What the Medical Community Needs to Know to Support Clients
Kate B. Daigle in The Clinical Guide to Fertility, Motherhood, and Eating Disorders, 2019
Currently only 16 of 50 states in the United States have infertility insurance coverage laws to assist those who qualify for fertility treatment, and four of these states have fertility preservation laws for iatrogenic (medically induced) infertility. Iatrogenesis means any adverse or unintended condition that occurs as a result of treatment for a medical condition. A common instance of iatrogenic infertility is cancer treatment, which can cause the body to go into early menopause and halt egg and hormone production. For a patient who lives in Arkansas, California, Connecticut, Delaware, Hawaii, Illinois, Louisiana, Maryland, Massachusetts, Montana, New Jersey, New York, Ohio, Rhode Island, Texas, or West Virginia and has insurance coverage, they may be eligible for assistance with fertility treatments (with qualifications varying state to state).15
Introduction
Rubin Battino in Using Guided Imagery and Hypnosis in Brief Therapy and Palliative Care, 2020
Again, here is Wikipedia information on iatrogenic and iatrogenesis (both are considered to be nosocomial):Iatrogenesis (from the Greek for “brought forth by the healer”) refers to any effect on a person, resulting from any activity of one or more persons acting as healthcare professionals or promoting products or services as beneficial to health, that does not support a goal of the person affected. Globally as of 2013 an estimated 20 million negative effects from treatment occurred. It is estimated that 142,000 people died in 2013 from adverse effects of medical treatment up from 94,000 in 1990. The term iatrogenic is defined as “induced in a patient by a physician’s activity, manner, or therapy. Used especially to pertain to a complication of treatment.” Furthermore, these estimates of death due to error are lower than those in a recent Institutes of Medicine report. If the higher estimates are used, the deaths due to iatrogenic causes would range from 230,000 to 284,000. Even at the lower estimate of 225,000 deaths per year, this constitutes the third leading cause of death in the U.S.
Environmental, Iatrogenic and Nutritional Disease
Jeremy R. Jass in Understanding Pathology, 2020
A major class of disease is iatrogenic disease caused by clinical management, particularly the administration of drugs with harmful side effects. Drug side effects are common, varied in their manifestations, and their consequences range from mild to life threatening. Nevertheless, drugs remain in use because their benefits greatly outweigh their potential for harm. The possibility that particular signs or symptoms could be drug induced must always be considered and explored by taking a full drug history. The link may be obvious if, for example, a skin rash occurs soon after the administration of an antibiotic, whereas the connection may be less obvious if the patient is on many drugs, the side effects are internal, the complication has not been described previously, and/or the presentation is obscured by symptoms or signs of other disease. In such cases a very high level of suspicion will be required in order to reach the correct diagnosis.
High utilisers of emergency departments: the profile and journey of patients with mental health issues
Published in International Journal of Psychiatry in Clinical Practice, 2021
Melissa Casey, Dinali Perera, Joanne Enticott, Hung Vo, Stana Cubra, Ashlee Gravell, Moana Waerea, George Habib
It has been further documented that those who present and receive too many services may also be vulnerable to iatrogenic injury or unintentional harm (Batavia and Batavia 2004). Iatrogenesis can be broadly defined as unintended or unnecessary harm arising from any aspect of health care management; and can be due to preventable human error or system failure (Runciman and Moller 2001). High utilisers may be at risk for errors resulting from poor transitional care, multiple handoffs (Lim and Warning 2016), and vulnerable to overtreatment, misdiagnosis, inappropriate pharmacologic therapy (Boltz 2013), and adverse events (Batavia and Batavia 2004). Research exploring experiences of adverse events, errors and multiple handoffs specifically for high utilisers with mental health conditions is however limited.
Person-centered versus disease-centered narratives among mental health providers in Kuwait: A critical and qualitative analysis of iatrogenesis and .global medical discourse in action
Published in International Journal of Mental Health, 2018
Several participants in this study felt that Kuwait is an overmedicated society, due to the overdiagnosis of mental disorders, such as anxiety, depression, and ADHD, for which the first course of action once a patient enters public healthcare facilities is a prescription. These prescriptions can sometimes lead to iatrogenically propagated drug-dependence, similar to North America (Frances, 2013; Greenberg, 2013). The only study fully addressing iatrogenic drug dependence in Kuwait was carried out in 1989 by A. M. Bilal, a psychiatrist in Kuwait, who pointed out, that after intravenous fluids and vitamins, the primary drugs given at a local psychiatric facility were benzodiazapines and neuroleptics (e.g., haloperidol and thioridazine) for the detoxification of patients who were already suffering from addictions (Bilal, 1989). According to his analysis, there was a shift between the use of illicit substances—which even today are primarily alcohol, heroin, hashish, and amphetamines—to benzodiazapines (Bilal, 1989). Several of the clinicians interviewed in this study provided similar narratives, suggesting that iatrogenesis persists in Kuwait and requires more attention from healthcare providers.
Just-in-Time Adaptive Interventions (JITAIs) for Suicide Prevention: Tempering Expectations
Published in Psychiatry, 2022
Craig J. Bryan, Heather Wastler, Nicholas Allan, Lauren R. Khazem, M. David Rudd
We applaud Coppersmith et al. for calling attention to the possibility that JITAIs could inadvertently cause harm by reducing the potency of otherwise effective suicide prevention treatments through habituation. At least two other potential risks warrant consideration: opportunity cost and iatrogenesis. First, JITAIs as standalone treatment options may cause harm by discouraging people from initiating other, more effective treatments, such as BCBT. If true, the overall benefit of increased access to JITAIs by people who otherwise would not access suicide prevention treatments could be nullified (or even reversed) by people who would have accessed suicide prevention treatments but decided not to because they used JITAIs instead. When evaluating the effectiveness of JITAIs, researchers should therefore consider how the risks and benefits of JITAIs compare to the risks and benefits of alternative treatment strategies to include empirically supported suicide prevention treatments.
Related Knowledge Centers
- Adverse Effect
- Amputation
- Antimicrobial Resistance
- Bacteria
- Drug Interaction
- Medical Sociology
- Medicalization
- Medical Prescription
- Hospital-Acquired Infection
- Medical Error